Aurinia Pharmaceuticals (AUPH) Set to Announce Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is set to post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Aurinia Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The business had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The business’s quarterly revenue was up 58.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.18) earnings per share. On average, analysts expect Aurinia Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $5.01 on Tuesday. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $12.43. The business has a fifty day moving average of $5.25 and a two-hundred day moving average of $7.17. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.99 and a current ratio of 5.50.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AUPH. Royal Bank of Canada dropped their price objective on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Cantor Fitzgerald cut their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. Finally, Jefferies Financial Group lowered their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.